The Global Atorvastatin API Market Size is estimated to be valued at USD 4,25,804.16 thousand and is expected to register a CAGR of 3.34% during the forecast period.

The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023. As per Global Atorvastatin API Market Analysis , the Global Market based companies will face certain challenges during the forecast period 2020 to 2027.

North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023. market report offers comprehensive study of the atorvastatin api manufacturing ,Overview, Regional Overview, Segments.

Segment Analysis

The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.

Market Players

Market Research Future (MRFR) recognizes Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India) as the key players in the global atorvastatin API market.

Regional Analysis

North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023.

The European market is estimated to exceed USD 1,31,094.04 thousand by 2023. High prevalence of hypercholesterolemia and mixed dyslipidemia are driving the growth of the Atorvastatin API market in the region. France is the major contributor to the growth of the regional market, followed by the UK.

Key Findings of the Study

The Global Atorvastatin API Market is projected to reach over USD 4,25,804.16 thousand by 2023 at 34% CAGR during the review period of 2018 to 2023.

North America accounted for the largest market share with the US being the major contributor to the growth of the market.

The hypercholesterolemia segment is projected to register the highest CAGR of 4.09% during the forecast period owing to the rising rate of hypercholesterolemia cases.

Key manufacturers are adopting geographic expansions, corporate acquisitions and product launches as growth strategies.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York, New York 10013,

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com